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ABSTRACT
Noncoding RNAs (ncRNAs), such as microRNAs and long noncoding RNAs 
(lncRNAs), participate in cellular transformation. Work done in the last decade 
has also demonstrated that ncRNAs with growth-inhibitory functions can undergo 
promoter CpG island hypermethylation-associated silencing in tumorigenesis. Herein, 
we wondered whether circular RNAs (circRNAs), a type of RNA transcripts lacking 
5′-3′ ends and forming closed loops that are gaining relevance in cancer biology, 
are also a target of epigenetic inactivation in tumors. To tackle this issue, we have 
used cancer cells genetically deficient for the DNA methyltransferase enzymes in 
conjuction with circRNA expression microarrays. We have found that the loss of DNA 
methylation provokes a release of circRNA silencing. In particular, we have identified 
that promoter CpG island hypermethylation of the genes TUSC3 (tumor suppressor 
candidate 3), POMT1 (protein O-mannosyltransferase 1), ATRNL1 (attractin-like 1) 
and SAMD4A (sterile alpha motif domain containing 4A) is linked to the transcriptional 
downregulation of both linear mRNA and the hosted circRNA. Although some circRNAs 
regulate the linear transcript, we did not observe changes in TUSC3 mRNA levels 
upon TUSC3 circ104557 overexpression. Interestingly, we found circRNA-mediated 
regulation of target miRNAs and an in vivo growth inhibitory effect upon TUSC3 
circ104557 transduction. Data mining for 5′-end CpG island methylation of TUSC3, 
ATRNL1, POMT1 and SAMD4A in cancer cell lines and primary tumors showed that the 
epigenetic defect was commonly observed among different tumor types in association 
with the diminished expression of the corresponding transcript. Our findings support 
a role for circRNA DNA methylation-associated loss in human cancer.
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INTRODUCTION
Approximately just 2% of the genome is transcribed 
into protein-coding RNAs [1], so the majority of 
transcripts are noncoding RNAs (ncRNAs), that can be 
categorized according to their structural properties and 
length [2]. Among the small ncRNAs, the most well-
studied class are microRNAs (19–25 nt) that control gene 
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expression through complementarity with target mRNAs 
[3]. In human tumors, miRNA expression patterns are 
distinct between normal tissues and derived malignancies, 
and between different tumor types [4, 5]. miRNAs can 
act as tumor suppressors or oncogenes, having a central 
role in oncogenesis [6]. Related to miRNAs showing 
growth inhibitory functions, their defects are associated 
with diverse mechanisms such as an impairment miRNA 
post-transcriptional regulation, targeted repression by 
oncogenes and the hypermethylation of the CpG island 
promoter located in the corresponding genomic locus 
from where the miRNA is transcribed [7, 8]. Long 
ncRNAs (lncRNAs; arbitrarily >200 nt) constitute 
another class of ncRNAs that, despite the lack of protein-
coding potential, commonly display mRNA-like features, 
such as poly(A) tails and multiexonic gene structures 
[2, 9]. LncRNAs are linked with a variety of functions, 
including splicing regulation, chromatin-related functions, 
and transcriptional control [2, 9]. Aberrant expression 
of lncRNAs in human tumors is common, and some 
lncRNAs have been demonstrated to act as oncogenes or 
tumor suppressors [2, 10]. The altered lncRNA expression 
of cancer cells can be associated with genetic events, such 
as copy number changes, but in an increasing number of 
cases, lncRNAs are targets of epigenetic silencing. In this 
regard, transcribed–ultraconserved regions [11, 12], small 
nucleolar RNAs [13], antisense RNAs [14] and other types 
of lncRNAs [15], have been demonstrated to undergo 
cancer-specific promoter CpG island hypermethylation-
associated loss.
Another novel and increasingly important class 
of noncodingRNAs are circular RNAs (circRNAs). 
CircRNAs are transcripts that lack 5′-3′ ends and 
poly(A) tails, forming a covalent closed loop 
[16, 17]. CircRNAs were first originally discovered in 
viruses in the 1970s [18], although they were mainly 
considered as transcriptional noise or splice errors. The 
recent re-discovery of circRNAs has been possible by 
the generalization of RNA sequencing methodology, 
particularly those that are not based on poly(A) 
purification, as well as new bioinformatic and quantitative 
PCR tools. Although some artificial circRNAs with an 
internal ribosome entry site (IRE) have been translated 
in vitro and a few endogenous circRNAs have been able 
to generate proteins, the evidence for their translation in 
the natural setting is limited [19] and most circRNAs are 
considered as ncRNAs. In this setting, the functions of 
circRNAs are diverse, with a proposed predominat role as 
miRNA sponges or decoys in association with their most 
common location in the cytoplasm, as well as exerting 
roles in protein scaffolding and in the regulation of RNA 
splicing and transcription [16, 17]. Most importantly, 
circRNA expression profiles are disrupted in many tumor 
types in comparison with their normal tissue counterparts 
[17, 20]. In this regard, some circRNAs have been 
characterized as pro-oncogenic, such as ciRS-7-A that 
enhances the EGFR/RAF1/MAPK pathway [21], or tumor 
suppressor molecules, such as circFoxo3 that prevent 
MDM2 activities [22]. 
Despite the growing evidence of the role of 
circRNAs in tumorigenesis, we know very little about how 
their expression and activity become disrupted in cancer 
cells. CircRNAs are thought to be mainly derived from the 
processing of precursor RNA (pre-mRNA) backsplicing of 
exons. A common scenario would be that a downstream 5′ 
splice site (donor) of an exon joins an upstream 3′ splice 
cite (acceptor) to originate the circRNA [16, 17]. Upstream 
defects in genes involved in pairing of complementary 
sequences and, thus, probably in backsplicing efficiency, 
can affect circRNA levels. This would be the case for 
the DexH-box helicase 9 (DHX9), adenosine deaminase 
acting on RNA-1 (ADAR1), fused in sarcoma (FUS), 
heterogeneous nuclear ribonucleoprotein (hnrNP) or 
Quaking (QKI) [17, 20]. Genomic aberrations can also 
contribute to abnormal circRNA activities, as it has been 
demonstrated by the identification of translocations that 
generate fusion circRNAs (f-circRNAs) that contribute 
to cellular transformation [23]. However, considering 
that many circRNAs are downregulated in cancer [24], 
and both tumor suppressor protein-coding genes [25] and 
the ncRNAs described above undergo DNA methylation-
associated silencing in tumors, we wondered if circRNAs 
are also targeted by this type of epigenetic inactivation. 
Herein, using genomic approaches that determine 
circRNA expression profiles vs DNA methylation patterns, 
we provide evidence that circRNAs, in conjuction with 
their corresponding linear RNAs, undergo cancer-specific 
hypermethylation-associated transcriptional silencing. 
These findings establish the epigenetic loss of circRNAs 
as another common characteristic of human tumors.
RESULTS
Cancer-specific promoter CpG island 
hypermethylation silences circular and host 
linear RNA
To identify cancer-specific candidate DNA 
methylation changes that affect circRNA expression, we 
used the experimental workflow displayed in Figure 1A. 
We took advantage of the development of an isogenic cell 
line obtained from the human colon cancer cell line HCT-
116, where the DNA methyltransferases 1 (DNMT1) and 
3B (DNMT3B) genes have been genetically disrupted by 
homologous recombination (double knockout cells, DKO) 
[26]. DKO cells show highly reduced DNMT activity, 
5-methylcytosine DNA levels and release of coding 
genes and lncRNA silencing associated with promoter 
CpG island hypomethylation [15, 26]. Supplementary 
Figure 1 shows by semiquantitative RT-PCR of mRNA 
and western blot that our DKO cells are deficient in the 
mentioned DNA methyltransferase enzymes. We sought 
to characterize tumor-specific DNA methylation events 
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in circRNA loci, so we also added a sample of normal 
colon mucosa in our screening strategy. To assess 
circRNA levels, total RNA from HCT-116, DKO and 
normal colon mucosa was analyzed using a previously 
validated circRNA microarray platform [27, 28]. Using 
this circRNA expression microarray, we interrogated a 
total of 4,998 human circRNAs. The circRNA microarray 
expression data obtained are available at the GEO 
repository under number GSE109676. According to 
their origins, these circRNAs can be classified as 4,637 
(92.7%) “Exonic” (arising from the exons of the linear 
transcript), 233 (4.7%) “Intronic” (arising from an 
intron of the linear transcript), 75 (1.5%) “Intragenic” 
(representing circRNAs transcribed from same gene locus 
as the linear transcript, but not classified into “exonic” 
and “intronic”), 52 (1.04%) “Antisense” (representing 
circRNAs whose gene loci overlap with the linear RNA, 
but that are transcribed from the opposite strand) and only 
one (0.02%) “Intergenic” (representing a circRNA located 
outside of any known gene loci). Using this expression 
platform, we identified 18 circRNAs (0.36% of the total 
4,998) that were not expressed in the colorectal cancer 
cell line HCT-116, but whose expression was restored 
in DKO cells and that were also expressed in normal 
colorectal mucosa. None of the circRNAs expressed in 
normal colorectal mucosa was overexpressed in HCT-
116 compared to DKO cells. All the DKO upregulated 
circRNAs were classified as “exonic” circRNAs included 
in 14 unique host genes. These circRNAs were FAM190B 
hsa_circRNA_100637, FAM190B hsa_circRNA_100638, 
FBXO9 hsa_circRNA_104122, GTF2IRD2 hsa_
circRNA_104402, IFT46 hsa_circRNA_100959, NEK11 
hsa_circRNA_103474, SGMS1 hsa_circRNA_100598, 
SLC37A3 hsa_circRNA_104510, ZNF532 hsa_
circRNA_102379, ACVR2A circ102830, TTBK2 
circ101496, TTBK2 circ101498, ATRNL1 circ100686, 
POMT1 circ104948, POMT1 circ104949, SAMD4A 
circ101356, TUSC3 circ104558 and TUSC3 circ104557. 
To characterize among these circRNAs those 
with tumor-specific differential promoter CpG 
island methylation of their respective host genes, we 
analyzed the DNA methylation profile of HCT-116 
cells, the derived DKO cells, and normal colon. DNA 
methylation patterns were determined using the Infinium 
HumanMethylation450 (450K) microarray, which 
includes 482,422 CpG sites [29]. We observed that 
among the 14 host genes that originated the 18 circRNAs 
identified above, the 5′-end CpG islands of the four 
protein coding genes TUSC3 (hosting TUSC3 circ104558 
and TUSC3 circ104557), ATRNL1 (hosting ATRNL1 
circ100686), POMT1 (hosting POMT1 circ104948 and 
POMT1 circ104949) and SAMD4A (hosting SAMD4A 
circ101356) were hypermethylated in HCT-116 cells and 
unmethylated in DKO cells and normal colon mucosa 
(Figure 1B). Thus, these four genes and their six hosted 
circRNAs became our main candidates to undergo cancer-
specific DNA methylation silencing and were studied in 
more detail. 
To confirm the existence of back-splicing for the six 
candidate circRNAs, we used divergent PCR primers that 
do not overlap the back-spliced exon-exon junctions to 
amplify specifically each candidate circRNA. Additional 
convergent PCR primers were used to corroborate the 
occurrence of transcription within these genomic loci. 
Using cDNA from the normal colon mucosa sample, 
we detected amplification with both convergent and 
divergent primers, except for TUSC3 circ104558 where 
only convergent PCR amplification was present (Figure 
2A). The presence of head-to-tail splicing of TUSC3 
circ104557, ATRNL1 circ100686, POMT1 circ104948, 
POMT1 circ104949 and SAMD4A circ101356 was 
validated by Sanger sequencing the PCR fragments 
amplified by divergent amplification primers (Figure 
2B). The microarray observed association between 
promoter CpG island hypermethylation of the host gene 
and both linear and circRNA low levels was confirmed 
by quantitative real-time PCR. TUSC3, ATRNL1, 
POMT1, and SAMD4A methylated HCT-116 cells 
showed downregulation of their linear and corresponding 
circRNAs (TUSC3 circ104557, ATRNL1 circ100686, 
POMT1 circ104948, POMT1 circ104949 and SAMD4A 
circ101356), whereas expression of both types of RNA 
transcript was restored in DKO cells (Figure 2C). The 
expression levels of both circular and linear transcripts 
normalized independently with three housekeeping genes 
(GAPDH/HPRT1/TBP) are shown in Supplementary 
Figure 2. Interestingly for the ten host genes that did not 
show DNA methylation differences between HCT-116 and 
DKO cells, the reactivation of the circular RNA in these 
last cells was not always significantly associated with a 
concordant reactivation of its corresponding linear RNA 
(Supplementary Figure 3), suggesting the existence in 
these cases of alternatives mechanisms of RNA regulation.
At the mechanistic level, circRNAs seem to 
possess different functionalities [16, 17, 20]. One 
possibility is that they regulate linear mRNA gene 
expression of the host gene [16, 17, 20]. In this regard, 
the cirRNAs ci-ankrd52, ElciEIF3j and circFoxo3 
upregulate the expression of their corresponding 
host genes ANKRD52 [30], EIF3J [31] and Foxo 3 
[22]. To assess the potential impact of the circRNAs 
studied herein upon the linear RNA derived from the 
host gene, we focused on TUSC3 circ104557 due 
to the well-recognized feature of its parental gene 
TUSC3 as a tumor suppressor gene [32]. To explore its 
potential activity, we transduced a TUSC3 circ104557 
lentiviral expression construct and the empty vector in 
the colorectal cancer cell lines studied. Upon efficient 
restoration of TUSC3 circ104557 expression in HCT-
116 cells (that exhibit DNA methylation-associated 
silencing of both the linear and the circRNA), we did 
not observe any reactivation of linear mRNA expression 
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of TUSC3 (Figure 3A). Importantly, the overexpression 
of TUSC3 circ104557 in DKO cells (that show an 
unmethylated status and expression of both linear and 
circRNA) did not change TUSC3 linear mRNA levels 
(Figure 3B). The expression levels of both circular and 
linear TUSC3 transcript normalized independently with 
three housekeeping genes (GAPDH/HPRT1/TBP) are 
shown in Supplementary Figure 4. Thus, the circRNA 
studied does not seem to function through the regulation 
of the linear RNA levels of its host gene.
Another possible activity of circRNAs is a role 
as miRNA sponges or decoys to regulate the levels of 
Figure 1: Screening for CpG island hypermethylation-associated silencing of circular RNAs in cancer cells. (A) Flow-
chart used to identify candidate circRNAs silenced in colon cancer through CpG island hypermethylation in the promoter region of their 
host genes. FC, Fold Change; SNP, Single Nucleotide Polymorphism. (B) DNA methylation profile of the 5′-end CpG island regulatory 
region for the TUSC3, ATRNL1, POMT1 or SAMD4A genes analyzed by the 450K DNA methylation microarray. DNA methylation data 
for healthy colon mucosa correspond to two normal colon patient samples available at TCGA  (Normal colon 1: TCGA-A6-2675-11A, 
sigmoid colon normal tissue; Normal colon 2: TCGA-A6-2685-11A, sigmoid colon normal tissue). Single CpG absolute methylation levels 
(0–1) are shown. Green, unmethylated; red, methylated. Data from normal colon, HCT-116 and DKO cells are shown.
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these molecules [16, 17]. To explore this function, we 
first used the colorectal cancer cell line HCT-116 (with 
DNA methylation associated silencing of the studied 
circRNAs) and the DKO cells (with demethylation-
associated reactivation of circRNAs due to the genetic 
disruption of DNMTs) and studied microRNAs that 
show base pair complementarity with the identified 
circRNAs. For HCT-116, we found that the epigenetic 
silencing of ATRNL1 circ100686, SAMD4A circ101356 
and TUSC3 circ104557 is associated with expression 
of their complementary miRNAs: hsa-miR-378a-3p 
(ATRNL1 circ100686), hsa-miR-330-3p and hsa-miR-
660-5p (SAMD4A circ101356) and hsa-miR-330-3p 
(TUSC3 circ104557), respectively. In contrast, the 
reactivation of these circRNAs in DKO was associated 
with a down-regulation of the described target miRNAs 
(Figure 3C). In a second experiment, we used the empty-
vector (mock) transduced HCT-116 cells in comparison 
with the TUSC3 circ104557 transduced HCT-116 
cell line. We observed that the efficient restoration of 
TUSC3 circ104557 in HCT-116 downregulates the 
expression levels of its candidate miRNA target, hsa-
miR-330-3p (Figure 3D). Thus, these data suppot a role 
of the studied circRNAs as miRNAs decoys. 
Once we demonstrated the presence of cancer-
specific promoter CpG island hypermethylation 
silencing of the described circRNAs and their 
proposed activity as miRNA sponges, we examined its 
contribution to the tumorigenic phenotype. We tested the 
ability of TUSC3 circ104557-transduced HCT-116 cells 
to form subcutaneous tumors in nude mice compared 
with empty vector-transduced cells. We found that 
empty vector cells formed tumors with a greater weight 
and volume, but TUSC3 circ104557-transduced HCT-
116 cells showed much lower tumorigenicity (Figure 
3E). TUSC3 circ104557 ectopic expression in tumors 
generated upon injection of HCT116-circTUSC3 cells 
in mouse flanks was confirmed by Real-time qPCR 
(Supplementary Figure 5). Thus, TUSC3 circ104557 
acts in our model as an inhibitor of tumor growth.
Figure 2: Characterization of TUSC3, ATRNL1, POMT1 and SAMD4A promoter CpG island hypermethylation-
associated silencing of circular and linear RNAs. (A) Convergent and divergent PCRs in normal colon, amplifying both circular 
and linear transcripts, or only the circular transcript, respectively. Since circRNAs encoded within POMT1 host gene shared a common 
sequence, convergent primers were designed for that region. Five out of six circRNAs were amplified in normal colon: ATRNL1 circ100686, 
POMT1 circ104948, POMT1 circ104949, SAMD4A circ101356 and TUSC3 circ104557. The TUSC3 circ104558 was not detected and it 
was excluded from the study. (B) Sanger Sequencing was used to sequence the head-to-tail junctions present in the fragments amplified by 
divergent PCR amplification. Chromatograms confirmed the occurrence of back-splicing. (C) Real-time quantitative PCR of both circular 
(top) and linear (below) transcripts in HCT-116 and DKO cells. Primers designed to amplify linear transcripts do not overlap annotated 
circRNAs according to circBase. Expression levels are relative to three housekeeping genes (GAPDH/HPRT1/TBP). Error bars, SD from 
three biological replicates. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Aberrant DNA methylation profiles of the 
circular and linear RNA loci identified are a 
common event in human tumorigenesis
The existence of tumor-specific promoter CpG 
island hypermethylation of the identified circRNA host 
genes was not a feature observed exclusively in the 
colorectal cancer cell line HCT-116. Data mining of a 
collection of 1,001 human cancer cell lines from the 
Sanger Institute, studied by the same DNA methylation 
microarray platform herein used, [33] confirmed the 
existence of hypermethylation of TUSC3, ATRNL1, 
POMT1 or SAMD4A in a significant proportion of these 
transformed cells across different tumor types (Figure 4A). 
The detailed analyses of the 5′-end CpG island methylation 
status of TUSC3, ATRNL1, POMT1 and SAMD4A in 
Figure 3: circRNA effects on linear transcripts, miRNAs and tumor growth. (A) Upon efficient transduction of TUSC3 
circ104557 in HCT-116 cells (harboring a methylated CpG island), the TUSC3 linear RNA levels did not change: it was not detected in 
any of the conditions tested. (B) TUSC3 circ104557 transduction in DKO cells (harboring an unmethylated CpG island) did not affect the 
levels of TUSC3 linear RNA. RNA levels were determined using circular or linear specific qRT-PCR primers. The lentiviral transduction of 
the empty vector (Mock condition) was used as a control. Experiments were performed in technical triplicates. (C) Expression of candidate 
miRNAs putatively targeted by ATRNL1 circ100686 (miR-378a-3p), SAMD4A circ101356 (miR-660-5p and miR-330-3p) and TUSC3 
circ104557 (miR-330-3p) was significantly downregulated in DKO cells, evaluated in three biological replicates by real-time quantitative 
PCR using TaqMan Advanced MicroRNA Assays. Expression levels were normalized using hsa-miR-345-5p, hsa-miR-191-5p and hsa-
miR-423-3p advanced Control miRNA Assays. (D) Using the same strategy, expression of miR-330-3p, putatively targeted by TUSC3 
circ104557, was also assessed in the gain-of-function cellular model. A significant downregulation of miR-330-3p was detected upon 
TUSC3 circ104557 transduction in HCT116 cells. (E) HCT116-Mock and HCT116-TUSC3 circular cells were injected in the left or right 
flank of 10 mice, respectively. Tumor volume measured over time (left panel) and tumor weight upon sacrifice (right panel) are shown. 
Tumor growth was significantly reduced upon TUSC3 circular ectopic expression. ns, nonsignificant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, 
using Student’s t-test. Error bars show means ± s.d.
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a set of 50 additional human colorectal cancer cell lines 
beyond HCT-116, including their microsatellite instability 
status, is shown in Supplementary Figure 6. In addition to 
colorectal cancer cell lines, the tumor type of the HCT-116 
cells used originally, each gene showed a characteristic 
profile of promoter hypermethylation. TUSC3 and 
ATRNL1 were predominantly methylated in cancer cell 
lines derived from the digestive system, such as stomach, 
pancreas and biliary tract, although their hypermethylation 
was also very common in hematological malignancies. 
POMT1 was found more frequently methylated in upper 
aerodigestive tract-derived tumors and esophagus, thyroid 
and soft tissue-originated cancer cell lines. SAMD4 
showed a mixed pattern in comparison to the other three 
genes with hypermethylation in digestive system-derived 
cells (stomach and colon), but also leukemia/lymphoma 
and esophagus. Interestingly, SAMD4 was the only gene 
displaying promoter hypermethylation in prostate-derived 
cancer cell lines. Most importantly, because expression 
microarray data for all these cell lines are available [33], 
we proceeded to compare the RNA levels and the DNA 
methylation status for the four identified circRNA host 
genes. We found that ATRNL1, POMT1, SAMD4A or 
TUSC3 promoter hypermethylation in the cell lines 
studied was associated with downregulation of their 
corresponding transcripts (Figure 4B). 
The occurrence of TUSC3, ATRNL1, POMT1 or 
SAMD4A promoter CpG island hypermethylation was not 
a restricted in vitro phenomenon of long-cultured cancer 
cell lines. Data mining of the collection of primary human 
tumors from The Cancer Genome Atlas (TCGA) project 
(https://cancergenome.nih.gov/), assessed by the same 
DNA methylation microarray used herein [29], showed the 
existence of 5′-end CpG island hypermethylation of these 
circRNA host genes in a wide spectrum of malignancies 
that resembled the cancer cell line data (Figure 5A). In 
this regard, 5′-end CpG island methylation of TUSC3, 
ATRNL1, POMT1 and SAMD4A was frequently 
observed in Colon Adenocarcinoma (COAD), Rectum 
Adenocarcinoma (READ), Stomach Adenocarcinoma 
(STAD), Lymphoid Neoplasm Diffuse Large B-cell 
Lymphoma (DLBC), Esophageal Carcinoma (ESCA), and 
Head-Neck Squamous Cell Carcinoma (HNSC). As we 
also did for the cancer cell lines, we were able to compare 
the TCGA described profiles for the four genes with the 
available RNA-sequencing data from the same primary 
tumor samples (https://cancergenome.nih.gov/). We 
observed that TUSC3, ATRNL1, POMT1 and SAMD4A 
5′-end CpG island methylation was again associated with 
downregulation of their corresponding transcripts (Figure 
5B), further tightening the link between the epigenetic 
mark and transcriptional inactivation.
DISCUSSION
Promoter CpG island hypermethylation-associated 
silencing of tumor suppressor genes is a hallmark of 
human cancer [34]. The coding genes affected by this 
Figure 4: Hypermethylation profiles for the circRNA host genes in cancer cell lines and their association with transcript 
down-regulation. (A) Percentage of TUSC3, ATRNL1, POMT1 and SAMD4A promoter CpG island hypermethylated samples in the 
Sanger panel of cancer cell lines by tumor type. “Haem.”, haematological; “Lymp”, lymphoid; “Aerodig.”, aerodigestive; “Upp.”, upper. 
(B) Promoter CpG island hypermethylation of the genes studied is significantly associated with downregulation of the corresponding 
transcript in the Sanger set of cancer cell lines. The box plots display the distribution of the expression values with the central solid line 
representing the median and the limits of the box, the upper and lower quartiles. The whiskers represent the minimum and maximum values 
excluding outliers (<1.5 × the interquartile range).
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epigenetic lesion cover all the molecular pathways related 
to cancer biology, such as DNA repair (BRCA1, MHL1 
and MGMT), cell cycle (p16INK4a and p15INK4b), apoptosis 
(DAPK and TMS1) or cell adherence (E-cadherin and 
cadherin-11) [34]. In the last decade, the increasingly 
recognized role of noncoding RNAs in carcinogenesis 
has also created a great interest in the area, and there 
are now many examples of different noncoding RNA 
subclasses that undergo DNA methylation-associated 
expression loss in tumorigenesis [34]. However, 
there are no reports studying the possible existence of 
aberrant DNA methylation events in the genomic loci 
that originate an emerging subtype of ncRNAs, the 
circRNAs. In this regard, it is important to fill this gap in 
our knowledge because circRNAs show drastic changes 
in their expression levels in human cancer, some of them 
have been shown to exert cellular activities as bona fide 
oncogenes or tumor suppressor genes, and they are starting 
to prove to be promising cancer biomarkers due their long 
half-life related to their resistance to RNA exonucleases 
[16, 17, 20].
Herein, using a combination of epigenomic and 
transcriptomic platforms, we have shown that certain 
circRNA genomic loci undergo cancer-specific DNA 
hypermethylation events. The gain of DNA methylation 
occurs at the CpG islands located at the 5′-end regulatory 
regions of the genes hosting the circRNAs. The promoter 
hypermethylation described silences both the linear RNA 
isoform of the parental gene and the circular RNA arising 
from back-splicing of the exons of the linear transcript. 
Thus, this is an example of how one epigenetic lesion in 
cancer can cause two molecular “hits”. A similar scenario 
has been described for bidirectional promoter-associated 
CpG islands that silence two genes simultaneously, as 
has been shown for WNT9A/CD558500, CTDSPL/
BC040563, and KCNK15/BF195580 [35]. 
Of the four identified genes hosting circRNAs that 
undergo hypermethylation-associated downregulation, 
Figure 5: Hypermethylation profiles for the circRNA host genes in primary tumors and their association with 
transcript down-regulation. (A) Percentage of TUSC3, ATRNL1, POMT1 and SAMD4A promoter CpG island hypermethylated cases 
in the TCGA panel of primary tumors by tissue type. Barr codes: Adrenocortical carcinoma (ACC), Bladder urothelial carcinoma (BLCA), 
Breast invasive carcinoma (BRCA), Cervical and endocervical cancers (CESC), Cholangiocarcinoma (CHOL), Colon adenocarcinoma 
(COAD), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC), Esophageal carcinoma (ESCA), FFPE Pilot Phase II (FPPP), 
Glioblastoma multiforme (GBM), Glioma (GBM/LGG), Head and Neck squamous cell carcinoma (HNSC), Kidney Chromophobe (KICH), 
Kidney renal clear cell carcinoma (KIRC), Kidney renal papillary cell carcinoma (KIRP), Acute Myeloid Leukemia (LAML), Brain 
Lower Grade Glioma (LGG), Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma 
(LUSC), Mesothelioma (MESO), Ovarian serous cystadenocarcinoma (OV), Pancreatic adenocarcinoma (PAAD), Pheochromocytoma 
and Paraganglioma (PCPG), Prostate adenocarcinoma (PRAD), Rectum adenocarcinoma (READ), Sarcoma (SARC), Skin Cutaneous 
Melanoma (SKCM), Stomach adenocarcinoma (STAD), Testicular Germ Cell Tumors (TGCT), Thyroid carcinoma (THCA), Thymoma 
(THYM), Uterine Corpus Endometrial Carcinoma (UCEC), Uterine Carcinosarcoma (UCS) and Uveal Melanoma (UVM). (B) Promoter 
CpG island hypermethylation of the genes studied is significantly associated with downregulation of the corresponding transcript in the 
TCGA panel of primary tumors. The box plots display the distribution of the expression values with the central solid line representing 
the median and the limits of the box, the upper and lower quartiles. The whiskers represent the minimum and maximum values excluding 
outliers (<1.5 × the interquartile range).
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only TUSC3 had been previously reported to be 
epigenetically inactivated in human cancer [32]. TUSC3 
epigenetic loss has been found in colorectal cancer, the 
same tumor type in which we initiated our screening, 
and it is associated with adverse prognosis [36]. Related 
to its candidate tumor suppressor function, the TUSC3 
protein localizes to the endoplasmic reticulum and is 
involved in protein glycosylation, enabling it to inhibit cell 
proliferation and promote both apoptosis and autophagy 
[37]. For the other three newly identified hypermethylated 
genes, POMT1 is involved in protein glycosylation (as 
also described above for TUSC3) and has been found 
to be related to the development of hematological 
malignancies [38], a tumor type also enriched in our cell 
line and TCGA methylation screening; ATRNL1 regulates 
energy homoeostasis and has been found inserted in the 
EML4-ALK fusion gene [39]; and SAMD4A is an RNA-
binding protein linked to drug resistance in cancer cells 
[40]. Our results pave the way to study the extent to which 
the putative tumor suppressor functions of these genes are 
associated with their linear RNA form, circular RNA form, 
or both.
In summary, our findings highlight that circRNAs 
undergo loss of expression in human cancer associated 
with hypermethylation of the 5′-end regulatory CpG 
island of their corresponding host genes. The promoter 
hypermethylation described is linked to the loss of both 
the linear and the circular RNA molecules. We have not 
observed a direct effect of the circRNA in the associated 
linear RNA level, however, it affects the levels of target 
miRNAs. Most importantly, the epigenetic events 
described at the circRNA genome loci are commonly 
observed among different types of human malignancies 
and their roles in the origin and progression of these 
tumors warrant further research.
MATERIALS AND METHODS
Human cancer cell lines
The human colon cancer cell line HCT-116 and 
its isogenic variant DKO were generous gifts from Dr 
Bert Vogelstein (Johns Hopkins Kimmel Comprehensive 
Cancer Center, Baltimore, MD, USA). All cell 
lines were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 10% FBS, penicillin and 
streptomycin, at 37º C in a humidified atmosphere of 5% 
(v/v) carbon dioxide. Cells were authenticated by STR 
profiling and tested for the absence of mycoplasma. 
circRNA expression microarray 
Total RNA was extracted using Trizol (Thermo 
Fisher Scientific) and three RNA biological replicates 
from each sample (HCT-116, DKO and normal colon 
mucosa) were quantified using the NanoDrop ND-1000 
and RNA were assessed by electrophoresis on a denaturing 
agarose gel. Sample labeling and array hybridization 
were performed according to the manufacturer’s protocol 
(Arraystar Inc.). Briefly, total RNA samples were treated 
with RNase R (Epicentre, Inc.) to remove linear RNAs. 
Then, each sample was amplified and transcribed into 
fluorescent cRNA utilizing a random priming method 
(Arraystar Super RNA Labeling Kit; Arraystar). The 
labeled cRNAs were purified by RNeasy Mini Kit 
(Qiagen). Both the concentration and specific activity 
of the labeled cRNAs (pmol Cy3/μg cRNA) were 
measured by NanoDrop ND-1000. 1 μg of each labeled 
cRNA was fragmented by adding 5 μl 10 × Blocking 
Agent and 1 μl of 25 × Fragmentation Buffer, then the 
mixture was heated at 60° C for 30 min. Finally, 25 μl 
2 × Hybridization Buffer was added to dilute the labeled 
cRNA. 50 μl of hybridization solution was dispensed 
into the gasket slide and assembled on the circRNA 
expression microarray slide. The labeled cRNAs were 
hybridized onto the Arraystar Human circRNA Array 
(8 × 15 K, Arraystar). The slides were incubated for 17 
hours at 65°C in an Agilent Hybridization Oven. The 
hybridized arrays were washed, fixed and scanned using 
the Agilent Scanner G2505C. Agilent Feature Extraction 
software (version 11.0.1.1) was used to analyze acquired 
array images. Quantile normalization and subsequent data 
processing were performed using the R software package. 
Differentially expressed circRNAs with statistical 
significance between two groups were identified through 
Volcano Plot filtering. Differentially expressed circRNAs 
between two samples were identified through fold change 
filtering.
Genome-wide DNA methylation analysis
Genome-wide DNA methylation analysis was 
performed with Illumina’s 450 K DNA methylation 
microarray (InfiniumHumanMethylation450 BeadChip) 
as previously described (29). After sodium bisulfite 
treatment with an EZ DNA Methylation-Gold kit (Zymo 
Research), we hybridized in the microarray DNA from 
the human colon cancer cell lines HCT-116 and DKO and 
from normal colon mucosa. A three-step normalization 
procedure was performed using the lumi package, 
available from Bioconductor, within the R statistical 
environment. This consisted of color-bias adjustment, 
background-level adjustment, and quantile normalization 
across arrays. The methylation level (β-value) of CpG 
sites was calculated as the ratio of methylated signal to 
the sum of methylated and unmethylated signals plus 100. 
Probes were considered to be in a promoter CpG island if 
they were located within a CpG island (UCSC database) 
and < 1,500 bp away from a transcription start site. 
Back-splicing of the candidate circular RNAs
Retro-transcribed cDNA corresponding to 50 ng 
of total RNA was amplified by PCR to confirm the 
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expression of the candidate circRNAs in normal colon 
(Ambion, Thermo Fisher Scientific, Cat. # AM7986). 
Divergent PCRs using primers that do not overlap the 
back-spliced exon-exon junction were used to specifically 
amplify each candidate circular RNA and to validate the 
existence of back-splicing. Additional convergent PCRs 
were used to corroborate the occurrence of transcription 
within these genomic loci. Importantly, the latter PCR 
amplify both linear and circular transcripts (one or 
more). Since circRNAs encoded within POMT1 host 
gene shared a common sequence, convergent primers 
were designed on that particular region. On the other 
hand, although there are two candidate circular RNAs 
encoded within the TUSC3 gene, they do not share a 
common sequence and specific convergent primers were 
designed accordingly. Since SAMD4A circ101356 is a 
monoexonic circular RNA, a RT- control was used in 
the convergent amplification, validating the absence 
of gDNA contamination. Sanger Sequencing (direct or 
through pGEM®-T vector cloning, Promega) was used 
to sequence the head-to-tail junctions present in the 
fragments amplified by divergent PCR amplification. 
The occurrence of back-splicing was confirmed by 
chromatogram analysis.
Quantitative PCR
Total RNA samples of the colon cancer cell lines 
HCT116 and DKO were purified using the Maxwell® 
RSC miRNA Tissue Kit (Cat. #AS1460, Promega) in 
the automated Maxwell® RSC Instrument (Promega), 
according to the manufacturer’s instructions. Human 
colon total RNA was obtained from Ambion, Thermo 
Fisher Scientific (Cat. # AM7986). Total RNAs were 
retro-transcribed using the ThermoScript™ RT–PCR 
System (Thermo Fisher Scientific), or GoScript Reverse 
Transcriptase (Promega), with random primer hexamers. 
Gene expression was determined by quantitative real-
time PCR using SYBR Green (Thermo Fisher Scientific) 
according to the manufacturer’s recommendations. 
Target gene expression levels were normalized to three 
housekeeping genes (GAPDH, HPRT1 and TBP). Some of 
the primers used to detect circular RNAs by divergent PCR 
were re-designed to overlap the back-spliced exon-exon 
junction in order to avoid unspecific RT-qPCR products. 
Primers designed to amplify linear transcripts do not 
overlap annotated circRNAs according to circBase [41]. 
Primer sequences are shown in Supplementary Table 1. 
Quantification of miRNA expression was performed using 
TaqMan Advanced MicroRNA Assays (ThermoFisher, 
Cat. No. A25576), according to the manufacturer’s 
instructions. In brief, TaqMan™ Advanced miRNA cDNA 
Synthesis Kit (ThermoFisher, Cat. No. A28007) was used 
for retrotranscription. Next, RT-qPCR was performed 
using TaqMan Fast Advanced Master Mix (ThermoFisher, 
Cat. No. 4444557) and specific TaqMan assays. Advanced 
Control miRNA Assays hsa-miR-345-5p, hsa-miR-191-5p 
and hsa-miR-423-3p (ThermoFisher, Cat. No. A25576) 
were used as endogenous controls. TaqMan assays IDs are 
listed in Supplementary Table 1. 
Validation of DNMT status in KO cells
In order to validate DNMT1 and DNMT3B 
knockout in DKO cells, semi-quantitative PCRs (30 
cycles) were performed using the primers listed in 
Supplementary Table 1. GAPDH was used as endogenous 
control. Knockout of DNMT1 and DNMT3B in DKO cells 
was also confirmed by western blot, using the following 
antibodies: Anti-DNMT1 from Boster, Cat No. Cl1105; 
and Anti-DNMT3B from Sigma, Cat. No. HPA001595. In 
both cases, membranes were incubated overnight in 1:500 
diluted antibodies in 5% Milk PBS-T. LaminB1 (Abcam, 
ab16048, 1:5000) was used as endogenous control.
Transduction
For the ectopic overexpression of TUSCS3_
circ104557, the cDNA corresponding to the circularized 
exons was amplified, adding artificial flanking sequences 
to promote circularization, as previously done [42]. 
Two sequential PCRs were performed to amplify 
the sequence comprising the circularized exons, the 
flanking regions and EcoRI or NotI restriction sites. 
This sequence was cloned into pLVX-ZsGreen1 plasmid 
from Clontech. 10 µg of each plasmid were mixed with 
7.5 µg of psPAX2 and 2.5 µg of pMD2.G plasmids in 1ml 
of JetPRIME buffer and 50 µl of JetPRIME (Polyplus-
transfection S.A.). Cloning oligonucleotides are shown in 
Supplementary Table 1. After 10 min of RT incubation, 
the transfection mix was added drop-wise to a 10-cm 
dish containing 10 ml of DMEM and Lenti-X 293T cells 
(Clontech) at 80% confluence to produce lentivirus. After 
72 h, the supernatant with high-titer lentiviral particles 
was recovered and 0.45-µm filtered. HCT-116 or DKO 
cells were incubated with 1.5 ml of concentrated viral 
supernatant supplemented with 10 μg/ml of polybrene 
(Santa Cruz Bitechnology) in six-well plates. A high 
transduction efficiency for all conditions was confirmed 
at the microscope by the presence of green fluorescence 
(ZsGreen1). 
Mouse xenografts
Five-week-old male athymic nu/nu mice (Charles 
River, Wilmington, MA, USA), housed under specific 
pathogen-free conditions, were used in this study. In 
order to assess tumor growth, 3.5 × 106 cells were 
subcutaneously injected in each flank of the mouse. The 
left flank was used for HCT116 control cells (mock) and 
the right for the circTUSC3 stably transduced HCT116 
cells. From day 13 after implantation, tumor growth 
was monitored every 3–5 days and the tumor width 
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(W) and length (L) were measured. Tumor volume was 
estimated according to the formula V = π/6 × L × W2. 
Mice were sacrificed 33 days after injection, and 
tumors were then excised and weighed. Then, tumor 
tissues were homogenized using liquid nitrogen, and 
RNA was extracted using the Maxwell® RSC miRNA 
Tissue Kit (Cat. #AS1460, Promega) in the automated 
Maxwell® RSC Instrument (Promega), according to the 
manufacturer’s instructions. After retrotranscription, 
circTUSC3 expression was quantified by real time PCR 
using the primers listed in Supplementary Table 1, as 
described above in Quantitative PCR section.
Statistical analysis
The associations between variables were assessed by 
χ2 tests, Fisher’s exact test, Welch’s t-test, Wilcoxon paired 
test or Spearman correlation whenever indicated. P values 
less than 0.05 were considered statistically significant. 
All statistical tests were two-sided. Methylation and 
expression values for TCGA primary tumor samples 
were obtained from the NCI’s Genomic Data Commons 
(GDC). The values corresponding to cancer cell lines were 
obtained from COSMIC cell line database. Correlations 
were obtained by calculating Spearman’s rank correlation 
test and the associated Rho coefficient.
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